296280-80-3Relevant academic research and scientific papers
Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands
Mésangeau, Christophe,Pérès, Basile,Descamps-Fran?ois, Carole,Chavatte, Philippe,Audinot, Valérie,Coumailleau, Sophie,Boutin, Jean A.,Delagrange, Philippe,Bennejean, Caroline,Renard, Pierre,Caignard, Daniel H.,Berthelot, Pascal,Yous, Sa?d
scheme or table, p. 3426 - 3436 (2010/11/04)
Novel heterodimer analogues of melatonin were synthesized, when agomelatine (1) and various aryl units are linked via a linear alkyl chain through the methoxy group. The compounds were tested for their actions at melatonin receptors. Several of these liga
Pictet-Spengler heterocyclizations via microwave-assisted degradation of DMSO
Mésangeau, Christophe,Yous, Sa?d,Pérès, Basile,Lesieur, Daniel,Besson, Thierry
, p. 2465 - 2468 (2007/10/03)
For the first time the ability of DMSO to decompose rapidly under microwaves was explored in order to perform heterocyclizations in good conditions. This modified Pictet-Spengler reaction allowed, in this case, the synthesis of rigidified melatonin analog
Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT3
Leclerc, Véronique,Yous, Sa?d,Delagrange, Philippe,Boutin, Jean A.,Renard, Pierre,Lesieur, Daniel
, p. 1853 - 1859 (2007/10/03)
The aim of this study was to synthesize selective ligands for melatoninergic subtype receptors that could elucidate the physiological role of melatonin (N-acetyl-5-methoxytryptamine, 1). So, we first investigated the role of a nitro substituent in the 4-,
Substituted dimeric compounds
-
, (2008/06/13)
The invention relates to compound of formula (I): A—G1—Cy—G2—Cy′—G3—B??(I) wherein: A represents a grouping NR1C(Q)R2, C(Q)NR2R3or NR1C(Q)NR2R3, B represents a grouping NR1C(Q)R2, NR1C(Q)NR2R3, C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2or NR2R3, G1and G3represent an optionally substituted alkylene chain, Cy and Cy′, which are different, represent a ring structure or G2represents a chain and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.
